RCM
IBER.U

Radcliffe Capital Management’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Radcliffe Capital Management’s Portfolio IBER.U Stock Details IBER.U Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-300,000
Closed -$2.96M – 996
2021
Q1 		$2.96M Buy
+300,000
New +$3M 0.12% 330

Other funds holding IBER.U

HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Radcliffe Capital Management's IBER.U Position: Q2 2021 in Review

Radcliffe Capital Management sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q2 2021, closing a stake of 300,000 shares — an estimated $2.96M sold.

Radcliffe Capital Management first reported a position in IBER.U in Q1 2021 and held it in 1 quarter. The position peaked at $2.96M in Q1 2021. 34 funds tracked by Wall St. Rank hold IBER.U as of Q2 2021.

  • Radcliffe Capital Management reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q2 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 300,000 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q2 2021, an estimated $2.96M.
  • Radcliffe Capital Management first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 1 quarter.
  • Radcliffe Capital Management's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $2.96M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q2 2021.

Based on Radcliffe Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.